KEN(SZ:300126)2023-04-21 16:00Financial Performance - The company's operating revenue for Q1 2023 was ¥115,573,893.86, a decrease of 6.11% compared to ¥123,094,949.31 in the same period last year[4]. - The net profit attributable to shareholders was a loss of ¥1,524,160.76, representing a decline of 209.70% from a profit of ¥1,389,429.63 in the previous year[4]. - The total operating costs for Q1 2023 were CNY 122,004,925.34, a decrease of 3.3% compared to CNY 127,035,971.45 in Q1 2022[20]. - The company's total comprehensive income for Q1 2023 was a loss of CNY 1,524,160.54, compared to a comprehensive income of CNY 1,389,430.12 in Q1 2022[21]. - Basic and diluted earnings per share for Q1 2023 were both CNY -0.01, compared to CNY 0 for Q1 2022[21]. Cash Flow - The net cash flow from operating activities increased by 148.40%, reaching ¥19,774,682.36, compared to a negative cash flow of ¥40,859,512.50 in the same period last year[4]. - The company reported a net cash flow from operating activities of CNY 19,774,682.36, a recovery from a negative cash flow of CNY 40,859,512.50 in the same period last year[24]. - The investment activities generated a net cash flow of CNY 5,579,314.92, down from CNY 27,099,254.14 in Q1 2022[24]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,317,193,294.58, a slight decrease of 0.58% from ¥1,324,874,266.38 at the end of the previous year[4]. - Total liabilities decreased to CNY 226,920,560.01 from CNY 233,077,371.27, indicating a reduction of 2.7%[17]. - The company's total current assets were CNY 633,931,469.22, down from CNY 677,679,580.70, a decline of 6.5%[16]. - Non-current assets increased to CNY 683,261,825.36 from CNY 647,194,685.68, showing an increase of 5.6%[16]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 16,206[10]. - The top shareholder, Wu Mingting, holds 26.65% of the shares, amounting to 81,000,000 shares[10]. Research and Development - R&D expenses increased, contributing to the net loss, alongside rising sales and management expenses[7]. - Research and development expenses increased to CNY 6,845,463.47, up 21.5% from CNY 5,636,808.44 in Q1 2022, reflecting a focus on innovation[20]. Inventory and Receivables - The company reported a decrease in accounts receivable from CNY 120,915,341.31 to CNY 96,528,597.90, a decline of 20.1%[15]. - The company’s inventory decreased from CNY 153,280,959.15 to CNY 142,306,330.78, a reduction of 7.2%[16]. Cash and Equivalents - Cash and cash equivalents increased to CNY 262,626,770.23 from CNY 229,694,004.16 at the beginning of the year, reflecting a growth of 14.3%[15]. - Cash and cash equivalents at the end of Q1 2023 were CNY 228,274,595.76, an increase from CNY 124,954,340.25 at the end of Q1 2022[24].